We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Former U.K. AstraZeneca R&D site to become science, technology park

Former U.K. AstraZeneca R&D site to become science, technology park

January 20, 2014
CenterWatch Staff

Loughborough, U.K., will be the location for a world-class science and technology park as development of a former AstraZeneca R&D site gets underway. Jayplas acquired the site in 2012 and has confirmed its plans to develop the site into a science park to be known as The Charnwood Biomedical Campus.

The 70-acre campus will provide multi-purpose, specialist laboratories and equipment, stability cabinets, a pilot plant, offices, warehousing and car parking for up to 1,500 vehicles.

The campus is expected to attract tenant businesses from a range of sectors including pharmaceuticals, life sciences, healthcare, new technology, R&D, academia and the public sector, in turn creating opportunities to bring jobs across these sectors back to Loughborough and the East Midlands.

“Charnwood Biomedical Campus will build on the legacy of 43 years of pharmaceutical research and development on the site in Loughborough,” said Dominic Young, director at Charnwood Biomedical Campus, who is leading the site’s redevelopment. “The campus will attract tenant businesses from new start-ups through to established enterprises that are looking to grow and develop in a dedicated and relevant environment. It will be the ideal location for businesses across a range of sectors including pharma, biotech, academia and government organizations.”

“The master plan builds on the existing facilities at the park and will see further investment and expansion as it grows to create a unique environment for businesses to base themselves,” he said.

Charnwood Biomedical Campus is a member of UKSPA (U.K. Science Park Association) and Medilink.

Europe Study Conduct

Upcoming Events

  • 16Dec

    Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

Featured Products

  • Regenerative-medicine-steps-to-accelerate-development-pdf

    Regenerative Medicine: Steps to Accelerate Development — PDF

  • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

    Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

Featured Stories

  • Ich_logo

    ICH Overhauls 22-Year-Old Clinical Studies Guideline

  • Survey_chart2019

    Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

  • China-360x240

    U.S. Tops List of Trial Startups With China Making Progress in Phase 1

  • Phoneapp-360x240

    Device Apps Present Unique Risks in Trials

New!

2019 Site Survey Reports

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing